This is a piece I wish existed in plain language when I was first researching ibogaine. There's information scattered across clinical papers, forum posts, and clinic intake forms, but almost nothing in one place that clearly explains which medications create real risk, why, and what the actual clearance timelines are.
This is that piece. It is not medical advice. It is a starting point for a conversation with your prescribing physician and with any clinic you're seriously considering.
Why this matters so much
Ibogaine's two primary safety concerns, cardiac risk and serotonin syndrome risk, are both significantly elevated by drug interactions. The single most reliable way to make ibogaine unsafe is to arrive at treatment with the wrong substances still in your system. The single most reliable way to prevent that is to understand what needs to clear, and when.
SSRIs and SNRIs
Examples: fluoxetine (Prozac), sertraline (Zoloft), escitalopram (Lexapro), paroxetine (Paxil), venlafaxine (Effexor), duloxetine (Cymbalta)
The risk: serotonin syndrome. Ibogaine acts on serotonin receptors; combining it with serotonin-active medications can cause serotonin levels to spike dangerously. Symptoms range from agitation and tremor to seizures and death.
The additional risk: SSRIs affect the CYP2D6 enzyme that metabolizes ibogaine, meaning ibogaine may accumulate to higher-than-expected levels in your system, amplifying both its effects and its cardiac profile.
Clearance: depends on the specific drug. Most SSRIs require a minimum of 2 weeks after the last dose. Fluoxetine (Prozac) has an extremely long half-life: its active metabolite (norfluoxetine) can take 4 to 6 weeks or longer to clear. This is the one that catches people off guard most often.
MAOIs
Examples: phenelzine (Nardil), tranylcypromine (Parnate), selegiline, some linezolid antibiotics, some migraine medications (specifically methylene blue)
The risk: potentially fatal interaction. MAOIs combined with serotonergic substances can cause severe serotonin syndrome. This is a hard contraindication.
Clearance: minimum 2 weeks after stopping an MAOI before ibogaine. Some clinicians recommend longer. No exceptions.
Opioids
Examples: heroin, fentanyl, oxycodone, hydrocodone, morphine, codeine, tramadol. Also buprenorphine (Suboxone, Subutex) and methadone. See the dedicated piece on these.
The situation: complicated and counterintuitive. Ibogaine is used specifically for opioid dependence. But the timing matters enormously.
If you arrive too soon after your last opioid use (when tolerance is still high), ibogaine's opioid-modulating effects may be blunted. If you arrive too long after (in severe acute withdrawal), the cardiac stress of withdrawal compounded by ibogaine's cardiac profile creates additional risk. The target is a specific window: mild to moderate withdrawal symptoms, not full crisis.
For short-acting opioids (heroin, oxycodone): most clinics prefer patients to be 12 to 24 hours past their last use: uncomfortable but not in crisis. Some clinics will actually administer short-acting opioids (typically oral morphine) on arrival to stabilize a patient in active withdrawal, then time the final dose 4 to 12 hours before ibogaine. This is a supervised clinical protocol, not something to replicate outside a medical setting.
Fentanyl is a distinct case. Despite its short plasma half-life, fentanyl accumulates in fat tissue and releases unpredictably over time, meaning patients may carry active drug far longer than expected. Clinics increasingly require extended clearance periods for fentanyl patients, and some will conduct urine or hair testing to assess clearance before proceeding.
7-hydroxymitragynine (the primary active opioid compound in kratom) requires specific attention. Many clinics require patients who use kratom to arrive several days early for a supervised washout, as 7-OH's complex alkaloid profile means the timeline for clearance is less predictable than standard opioids.
For long-acting opioids and MAT medications: see the separate piece.
Stimulants
Examples: cocaine, methamphetamine, Adderall (amphetamine), Ritalin (methylphenidate)
The risk: cardiac. Stimulants increase heart rate and blood pressure and have their own QT effects. Combined with ibogaine's QT prolongation, the interaction can be dangerous.
Clearance: cocaine: minimum 24 to 48 hours. Methamphetamine: 48 to 72 hours. Prescription stimulants: discuss with your clinic, as some require 2 to 4 weeks for ADHD medications, particularly if you have any cardiac concern.
Benzodiazepines
Examples: Xanax (alprazolam), Valium (diazepam), Klonopin (clonazepam), Ativan (lorazepam)
The situation: nuanced. Benzos don't have a direct dangerous interaction with ibogaine the way SSRIs and stimulants do. In fact, some clinicians use low-dose benzos to manage anxiety or agitation during ibogaine treatment.
The risk is in stopping them. Benzodiazepine withdrawal can cause seizures, particularly at higher doses or after long-term use. You should not abruptly stop benzos before ibogaine. A supervised taper with your prescribing physician is the right path.
Also worth knowing: benzos can blunt the ibogaine experience. Patients who arrive with significant benzo tolerance may find the medicine less effective.
Lithium and mood stabilizers
Examples: lithium, valproate (Depakote), lamotrigine (Lamictal)
The risk: lithium in particular lowers the seizure threshold and may increase cardiac risk in combination with ibogaine. Most responsible clinics consider active lithium use a contraindication.
Clearance and tapering: requires physician supervision. Do not stop lithium abruptly.
Antipsychotics
Examples: quetiapine (Seroquel), olanzapine (Zyprexa), risperidone, aripiprazole (Abilify), haloperidol
The risk: many antipsychotics also prolong the QT interval. Combined with ibogaine, the additive effect on QT can be significant. Most clinics consider active antipsychotic use a relative or absolute contraindication depending on the specific medication and cardiac baseline.
A note on supplements
Some supplements that seem benign carry interaction risks with ibogaine. High-dose 5-HTP (a serotonin precursor) can contribute to serotonin syndrome risk. St. John's Wort is an MAOI-adjacent serotonin modulator. If you're taking supplements regularly, include them in your intake disclosure.
The practical guidance
Make a complete list of everything you take (prescription, over-the-counter, supplement) and share it fully with any clinic you're considering at the beginning of the conversation, not the end. The clinics worth working with will take this information seriously and give you clear guidance. The ones who don't ask or don't seem to care are telling you something important.
One more thing worth knowing: reputable Mexico clinics will drug test you on arrival. This isn't punitive. It's how they establish exactly what's in your system before making final dosing and timing decisions. If you arrive on a medication you didn't disclose, the clinic will find out, and the result will be a detox period on-site before treatment can proceed. That's extra time, extra cost, and a harder experience than it needed to be. Arrive honest.